Health News

Lupine launches Valentas and Arnipin for treating heart failure patients

Mumbai: Lupine Limited has announced the launch of the combination drug sacubitril and valsartan under the brand name Valentine’s and Arnipin, in India. This drug combination is indicated for patients with heart failure (HF) conditions.

Valentas and Arnipin tablets are available in 200 mg, 100 mg, and 50 mg, and are indicated to reduce repeated hospitalizations and the risk of cardiovascular death among adult patients with moderate chronic to mild heart failure.

In India, HF remains one of the most prevalent causes of death in patients suffering from chronic heart failure. The estimated prevalence of HF ranges from 1.3 to 4.6 million currently. In addition, the HF pattern in India is considered different from the rest of the worlddue to factors such as the high prevalence of hypertension and diabetes, the average age of Indian patients with HF being ten years younger than the global average, and the limited adoption of guideline-directed medical therapy.

Commenting on the launch, Rajeev Sibal, President, India Region Formulations, Lupine said, “Heart failure is a difficult condition with severe unmet needs, necessitating the development of treatment agents to improve patient outcomes, Valentas and Arnipin offer patients an important treatment option to fulfill this unmet need, while reducing the cost of therapy.”




Source link

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button